Showing results (71-80 of 202) with videos related to
Sort By:
Pageof 21
Molecular Cancer Therapeutics|March 21, 2006
Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of AktJoell J Gills, Susan Holbeck, Melinda Hollingshead, et al.Journal of Medicinal Chemistry|October 13, 2009
Searching for new cures for tuberculosis: design, synthesis, and biological evaluation of 2-methylbenzothiazolesQingqing Huang, Jialin Mao, Baojie Wan, et al.Bioorganic & Medicinal Chemistry Letters|September 9, 2008
Modification of the side chain of micromolide, an anti-tuberculosis natural productHai Yuan, Rong He, Baojie Wan, et al.Journal of Medicinal Chemistry|May 23, 2008
A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparumYufeng Chen, Miriam Lopez-Sanchez, Doris N Savoy, et al.Bioorganic & Medicinal Chemistry Letters|September 25, 2003
Synthesis and pharmacological evaluation of (Z)-9-(heteroarylmethylene)-7-azatricyclo[4.3.1.0(3,7)]decanes: thiophene analogues as potent norepinephrine transporter inhibitorsJia Zhou, Thomas Kläss, Ao Zhang, et al.Journal of Molecular Modeling|May 15, 2009
Use of molecular modeling, docking, and 3D-QSAR studies for the determination of the binding mode of benzofuran-3-yl-(indol-3-yl)maleimides as GSK-3beta inhibitorsKi Hwan Kim, Irina Gaisina, Franck Gallier, et al.Chemmedchem|January 9, 2008
Chemistry, biology, and QSAR studies of substituted biaryl hydroxamates and mercaptoacetamides as HDAC inhibitors-nanomolar-potency inhibitors of pancreatic cancer cell growthAlan P Kozikowski, Yufeng Chen, Arsen M Gaysin, et al.Journal of Medicinal Chemistry|May 28, 2004
Synthesis, molecular modeling, and biological studies of novel piperidine-based analogues of cocaine: evidence of unfavorable interactions proximal to the 3alpha-position of the piperidine ringPavel A Petukhov, Jianrong Zhang, Cheng Z Wang, et al.Expert Opinion on Investigational Drugs|April 25, 2009
Putting the 'HAT' back on survival signalling: the promises and challenges of HDAC inhibition in the treatment of neurological conditionsSama F Sleiman, Manuela Basso, Lata Mahishi, et al.Molecular Cancer Therapeutics|April 18, 2003
Specific inhibition of the Akt1 pleckstrin homology domain by D-3-deoxy-phosphatidyl-myo-inositol analoguesEmmanuelle J Meuillet, Daruka Mahadevan, Hariprasad Vankayalapati, et al.Pageof 21